Document:

Amendment to Settlement Agreement

 EXHIBIT 10.83 
 AMENDMENT TO SETTLEMENT AGREEMENT 
 WHEREAS, on or about July 11, 2007, a settlement agreement
(the “Settlement Agreement”) was entered into among the United States of America, acting through its Department of Justice and the United States Attorney’s Office for the Eastern District of New York, the Office of Inspector General
of the Department of Health and Human Services (“HHS-OIG”), the United States Office of Personnel Management (“OPM”), and the United States Department of Defense TRICARE Management Activity (“TMA”) (collectively the
“United States”); Jazz Pharmaceuticals, Inc. (“JPI”) and Orphan Medical, Inc. (which merged in 2008 into Orphan Medical, LLC) (“Orphan”) (JPI and Orphan are collectively referred to as “Defendants”); and
Shelley Lauterbach (the “Relator”); through their authorized representatives (collectively, all of the above will be referred to as “the Parties”); 
 WHEREAS, the Settlement Agreement resolved certain claims that the United States and Relator had against Defendants regarding the marketing of the drug Xyrem, including claims under the federal False Claims Act;

 WHEREAS, in accordance with the Settlement Agreement, Defendants agreed to make payments to the United States pursuant to a schedule
annexed to the Settlement Agreement (the “Schedule”); 
 WHEREAS, the Settlement Agreement requires Defendants to make a payment to
the United States on January 15, 2009; 
 WHEREAS, due to a change in their financial condition, Defendants have requested that the
Schedule be amended so that their January 15, 2009 payment becomes due on October 15, 2009; 
 WHEREAS, following the United States
review of Defendants’ current financial condition, the United States and Relator consent to such an amendment of the Settlement Agreement; 
  

					
	 Amendment to Civil Settlement Agreement
 with Jazz Pharmaceutical, Inc/Orphan Medical
	  	1	  	

 THEREFORE, the Parties hereby agree to the following: 
 1. The Schedule is amended as follows: Defendants’ January 15, 2009 payment to the United States is now due on October 15, 2009.

 2. Defendants and Relator represent that this Amendment is freely and voluntarily entered into without any degree of duress or compulsion
whatsoever. 
 3. The individuals signing this Amendment on behalf of Defendants represent and warrant that they are authorized by Defendants
to execute this Amendment. The individual signing this Amendment on behalf of Relator represents and warrants that he is authorized by Relator to execute this Amendment. The United States signatories represent that they are signing this Amendment in
their official capacities and that they are authorized to execute this Amendment. 
 4. This Amendment may be executed in counterparts, each
of which constitutes an original and all of which constitute one and the same Amendment. 
 5. This Amendment is binding on Defendants’
successors, transferees, heirs, and assigns. 
 6. This Amendment is binding on Relator’s successors, transferees, heirs, and assigns.

 7. All Parties consent to the United States’ disclosure of this Amendment, and information about this Amendment, to the public.

 8. This Amendment is effective on the date of signature of the last signatory to the Amendment (the “Effective Date of this
Amendment”). Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this Amendment. 
  

					
	 Amendment to Civil Settlement Agreement
 with Jazz Pharmaceutical, Inc/Orphan Medical
	  	2	  	

 THE UNITED STATES OF AMERICA 
  

									
		 		 	BENTON J. CAMPBELL
		 		 	United States Attorney
		 		 	Eastern District of New York
					
	DATED:	 	2/4/09	 		 	BY:	 	/s/ Paul Kaufman
		 		 		 		 	PAUL KAUFMAN
		 		 		 		 	Assistant United States Attorney
		 		 		 		 	Chief, Civil Health Care Fraud
		 		 		 		 	United States Attorney’s Office
		 		 		 		 	Eastern District of New York
					
	DATED:	 	2/4/09	 		 	BY:	 	/s/ Brian McCabe
		 		 		 		 	BRIAN McCABE
		 		 		 		 	Trial Attorney
		 		 		 		 	Commercial Litigation Branch
		 		 		 		 	Civil Division
		 		 		 		 	United States Department of Justice
					
	DATED:	 	2/18/09	 		 	BY:	 	/s/ Gregory E. Demske
		 		 		 		 	GREGORY E. DEMSKE
		 		 		 		 	Assistant Inspector General for Legal Affairs
		 		 		 		 	Office of Counsel to the Inspector General
		 		 		 		 	Office of Inspector General
		 		 		 		 	United States Department of Health and Human Services
					
	DATED:	 	2/10/09	 		 	BY:	 	/s/ Laurel C. Gillespie
		 		 		 		 	LAUREL C. GILLESPIE
		 		 		 		 	Deputy General Counsel
		 		 		 		 	TRICARE Management Activity
		 		 		 		 	United States Department of Defense

  

					
	 Amendment to Civil Settlement Agreement
 with Jazz Pharmaceutical, Inc/Orphan Medical
	  	3	  	

									
					
	DATED:	 	2/3/06	 		 	BY:	 	/s/ Lorraine E. Dettman
		 		 		 		 	LORRAINE E. DETTMAN
		 		 		 		 	Assistant Director for Insurance Service Programs
		 		 		 		 	Center for Retirement and Insurance Services
		 		 		 		 	United States Office of Personnel Management
					
	DATED:	 	2/4/09	 		 	BY:	 	/s/ J. David Cope
		 		 		 		 	J.DAVID COPE
		 		 		 		 	Assistant Inspector General For Legal Affairs
		 		 		 		 	United States Office of Personnel Management

  

					
	 Amendment to Civil Settlement Agreement
 with Jazz Pharmaceutical, Inc/Orphan Medical
	  	4	  	

 JPI AND ORPHAN - Defendants 
  

									
					
	DATED:	 	2/6/09	 		 	BY:	 	/s/ Samuel R. Saks
		 		 		 		 	SAMUEL R. SAKS, M.D.
		 		 		 		 	Chief Executive Officer
		 		 		 		 	Jazz Pharmaceuticals, Inc
					
	DATED:	 	2/6/09	 		 	BY:	 	/s/ Bob Myers
		 		 		 		 	ROBERT MYERS.
		 		 		 		 	Member
		 		 		 		 	Orphan Medical, LLC
					
	DATED:	 	2/6/09	 		 	BY:	 	/s/ Mark Jensen
		 		 		 		 	J. SEDWICK SOLLERS III, Esq.
		 		 		 		 	MARK A. JENSEN, Esq.
		 		 		 		 	King & Spalding LLP
		 		 		 		 	Counsel for Jazz Pharmaceuticals Inc. and
		 		 		 		 	Orphan Medical, LLC

  

					
	 Amendment to Civil Settlement Agreement
 with Jazz Pharmaceutical, Inc/Orphan Medical
	  	5	  	

 RELATOR 
  

									
					
	DATED:	 	2/4/09	 		 	BY:	 	/s/ Shelley Lauterbach
		 		 		 		 	SHELLEY LAUTERBACH
		 		 		 		 	Relator
					
	DATED:	 	2/4/09	 		 	BY:	 	/s/ Larry Zoglin
		 		 		 		 	LARRY ZOGLIN, Esq.
		 		 		 		 	Phillips and Cohen LLP
		 		 		 		 	Counsel for Relator

  

					
	 Amendment to Civil Settlement Agreement
 with Jazz Pharmaceutical, Inc/Orphan Medical
	  	6Exclusive License Agreement - The Regents of the University of California

 Exhibit 10.4 
 EXCLUSIVE LICENSE AGREEMENT 
 between 
 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 and 
 NEUROGESX, INC. 
 for 
 HIGH DOSE CAPSAICIN FOR NEUROPATHIC PAIN 
 UCSF Case No. SF00-056 

 UC Case No. SF00-056 
 EXCLUSIVE LICENSE AGREEMENT 
 For 
 HIGH DOSE CAPSAICIN FOR NEUROPATHIC PAIN 
 This license agreement (the “Agreement”) is made
effective November 1, 2000 (the “Effective Date”) between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200,
(“The Regents”), and acting through its Office of Technology Management, University of California San Francisco, 1294 Ninth Avenue – Suite 1, Box 1209, San Francisco, CA 94143-1209 (“UCSF”), and NEUROGESX, INC., a
Delaware corporation having a principal place of business at 2215 Bridgepointe Parkway, Suite 200, San Mateo, California, (the “Licensee”). 
 BACKGROUND 
 A. Certain inventions, generally characterized as “High Dose Capsaicin Relieves
Neuropathic Pain” (collectively the “Invention”), were made in the course of research at the University of California San Francisco by Wendye R. Robbins as described in UCSF Case Number SF00-056, and are covered by Regents’
Patent Rights as defined below; 
 B. The Licensee has evaluated the Invention under a Secrecy Agreement with The Regents effective
August 20, 1999 (U.C. Control No. 2000-20-0104); 
 E. The Licensee and The Regents have executed a Letter of Intent dated
June 1, 2000 (U.C. Control No. 2000-30-0050) for the purpose of negotiating a license to Regents’ Patent Rights; 
 F. The
Licensee wishes to obtain rights from The Regents for the commercial development, use, and sale of products from the Invention, and The Regents is willing to grant those rights so that the Invention may be developed to its fullest and the benefits
enjoyed by the general public; and 
 G. The Licensee is a “small business firm” as defined in 15 U.S.C. §632; 
 H. Licensee recognizes and agrees that royalties due under this Agreement will be paid on both pending patent applications and issued patents;

 In view of the foregoing, the parties agree: 
 1. DEFINITIONS 
 1.1 “Regents’ Patent Rights” means the Regents’ interest in any subject matter claimed in or
covered by any of the following: Pending U.S. Patent Application Serial No. 08/746,207 entitled “Therapeutic Method with Capsaicin and Capsaicin Analogs” filed November 6, 1996, the 

 
continuation-in-part U.S. Patent Application Serial No. 08/990,633 entitled “Transdermal Therapeutic Device and Method with Capsaicin and Capsaicin
Analogs” filed December 15, 1997 and assigned to The Regents; and continuing applications thereof including divisions, substitutions, continuation-in-part applications (but only to the extent however, that claims in the
continuation-in-part applications are entitled to the priority filing date of the foregoing applications); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding foreign applications or
patents based on said applications. 
 1.2 “Licensed Product” means any material for which the manufacture, use, sale, or import
would constitute an infringement of a Valid Claim within the Regents’ Patent Rights if not for the license granted to the Licensee under this Agreement. 
 1.3 “Licensed Method” means any method for which the use or sale would constitute an infringement of a Valid Claim within the Regents’ Patent Rights if not for the license granted to the Licensee under
this Agreement. 
 1.4 “Net Sales” means the total of the gross invoice prices of Licensed Products sold or Licensed Methods
performed by the Licensee, an Affiliate, or a Sublicensee, less the sum of the following actual and customary deductions where applicable: cash, trade, or quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed on
particular sales; transportation charges and allowances (including insurance); or credits to customers because of rejections, returns, or expired goods. For purposes of calculating Net Sales, transfers to an Affiliate or Sublicensee for end use by
the Affiliate or Sublicensee will be treated as sales to an independent third party for purposes of calculating earned royalties (as specified in Article 7) 
 1.5 “Affiliate” means any corporation or other business entity in which the Licensee owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting
rights entitled to elect directors, or in which the Licensee is owned or controlled directly or indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the
local law does not permit foreign equity participation of at least fifty percent (50%), then an “Affiliate” includes any company in which the Licensee owns or controls or is owned or controlled by, directly or indirectly, the maximum
percentage of outstanding stock or voting rights permitted by local law. 
 1.6 “Field of Use” means all fields and uses.

 1.7 “Commercial Sale” means with respect to each Licensed Product in each country, a bona fide commercial sale of such Licensed
Product following marketing approval by the regulatory authority in such country; provided that where such a first commercial sale has occurred in a country for which government pricing or government reimbursement approval is needed for widespread
commercial sale (for clarification, the parties acknowledge that no such approval is required in the United States) then a sale shall not be deemed a Commercial Sale until such pricing or reimbursement approval has been obtained. 
  

 -2- 

 1.8 “IND” means an Investigational New Drug Application, as defined in the U.S. Federal Food,
Drug and Cosmetic Act and the regulations promulgated thereunder, or comparable filing in a foreign jurisdiction, in each case with respect to a Licensed Product. 
 1.9 “NDA” means a New Drug Application, as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, and all subsequent supplements to that NDA, as well as any equivalent
foreign application, registration or certification in the relevant country, such as a Marketing Approval Application (“MAA”) in Europe, in each case with respect to a Licensed Product. 
 1.10 “Phase I” means a clinical trial involving the initial introduction of a Licensed Product into humans and which is designed to determine
the metabolism and pharmacologic actions of the Licensed Product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. 
 1.11 “Phase III” means human clinical trials of a Licensed Product performed after obtaining preliminary evidence suggesting effectiveness of
the drug, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug, to provide an adequate basis for physician labeling, and to form the basis
for approval to market such Licensed Product. 
 1.12 “Valid Claim” means a claim of an issued and unexpired patent or a claim of a
pending patent application within the Regents’ Patent Rights which has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken, and has not been
admitted to be invalid or unenforceable through re-examination, disclaimer or otherwise; provided that if a claim of a pending application has not issued as a claim of an issued patent within the Regents’ Patent Rights within ten
(10) years after the filing date from which such claim takes priority, such pending claim shall not be a Valid Claim for purposes of this Agreement until such time as such claim issues. 
 1.13 “Sublicensee” means, with respect to a particular Licensed Product, a third party to whom Licensee has granted a right or license to both
make and sell such Licensed Product or practice the Licensed Method. As used in this Agreement, “Sublicensee” shall also include a non-Affiliate third party to whom Licensee has granted a right to distribute such Licensed Product, provided
that such third party is responsible for some or all of the marketing and promotion of such Licensed Product within the territorial region in which it has such sublicensed rights. 
 2. LIFE OF PATENT EXCLUSIVE GRANT 
 2.1 Subject to the limitations set forth in this Agreement, The Regents
grants to the Licensee a world-wide license under Regents’ Patent Rights to make, have made, use, sell, offer to sell, import and have imported Licensed Products, to practice Licensed Methods, and to otherwise exploit the Regents’ Patent
Rights, and to have each of the foregoing performed by a third party on Licensee’s behalf. 
  

 -3- 

 2.2 Except as otherwise provided in this Agreement, the license granted in Paragraph 2.1 is
exclusive for the life of this Agreement. 
 2.3 The license granted in Paragraphs 2.1 and 2.2 is limited to methods and products that
are within the Field of Use. For other methods and products, the Licensee has no license under this Agreement. 
 2.4 To the extent it is
legally able, The Regents also grants Licensee a non-exclusive license to any proprietary know-how relating to Regents’ Patent Rights that The Regents has an interest in and is reasonably needed by Licensee to practice and/or commercially
develop Licensed Products and/or Licensed Methods. 
 2.5 The Regents reserves the nontransferable right to use the Invention and associated
technology for its own bona fide non-commercial research and education purposes. 
 3. SUBLICENSES 
 3.1 The Regents also grants to the Licensee the worldwide right to issue sublicenses to third parties to make, have made, use, sell, offer to sell, import
and have imported Licensed Products, to practice Licensed Methods, and to otherwise exploit the Regents’ Patent Rights, in each case as long as the Licensee has current exclusive rights thereto under this Agreement. Each sublicense shall be
subordinate to the terms and conditions of this Agreement (including, if applicable, those regarding the U.S. Government’s and other sponsors’ rights and the rights reserved by The Regents). 
 3.2 In addition, Licensee shall pay The Regents a percentage of all sublicense fees (as defined below). 
 3.2.1 For purposes of this Agreement, “sublicense fees” shall consist of amounts received in the form of up-front fees and milestone
payments as direct consideration for the grant of a sublicense for Licensed Products under the Regents’ Patent Rights, but shall not include any amounts received as royalties on sales of Licensed Products, as support for research and
development activities, as a loan, as income derived from debt financing, for the purchase of an equity interest in the Licensee, as reimbursement for patent and patent related expenses, as earned royalties on net sales, or as consideration for the
grant of intellectual property rights and materials other than those claimed under Regents’ Patent Rights. Licensee shall pay The Regents the following percentages of sublicense fees: 
  

			
	 Percentage
	  	Aggregate Sublicense Fees
	 25%
	  	< $250,000
	 10%
	  	$250,000 — $2,000,000
	 5%
	  	> $2,000,000

  

 -4- 

 3.2.2 For purposes of calculating the applicable percentage for the foregoing, “Aggregate Sublicense
Fees” shall be the cumulative amount of sublicense fees stated in each sublicense of Regents’ Patent Rights entered into by Licensee and assuming that all milestone payments therein are made to Licensee. However, the actual
sublicensee fee payments due The Regents from Licensee shall be determined based on the actual amounts of sublicensee fees received by Licensee in each calendar year during the term of this Agreement. 
 3.3 The Licensee shall promptly provide The Regents with a copy of each sublicense issued; collect all payments due The Regents from Sublicensees; and
summarize and deliver all reports due The Regents from Sublicensees, provided that the Licensee may redact from such copy any terms which are not necessary to determine whether Licensee has complied with its obligations under this Agreement.

 3.4 Upon termination of this Agreement for any reason, any sublicense granted by Licensee hereunder shall survive, provided that upon
request by The Regents, each Sublicensee promptly agrees in writing to be bound by the applicable terms of this Agreement.. 
 4. PAYMENT TERMS 

4.1 Licensee shall pay to The Regents earned royalties (as specified in Section 7) on Net Sales of Licensed Products on a Licensed
Product-by-Licensed Product and country-by-country basis. The earned royalty due pursuant to this Section will continue on such basis until the manufacture, use or sale of a Licensed Product in such country does not infringe a Valid Claim
within the Regents’ Patent Rights. 
 4.2 Licensee shall pay earned royalties quarterly on or before February 28,
May 31, August 31 and November 30 of each calendar year. Each payment will be for earned royalties accrued within the Licensee’s most recently completed calendar quarter. 
 4.3 Licensee shall pay the applicable percentage of sublicense fees to The Regents on or before February 28 of each calendar year. Each
payment will be for sublicensee fees received by Licensee during the most recently completed calendar year. 
 4.4 [Intentionally left
blank] 
 4.5 All monies due The Regents are payable in United States dollars. When Licensed Products are sold for monies other than United
States dollars, the Licensee shall first determine the applicable earned royalty in the currency of the country in which Licensed Products were sold and then convert the amount into equivalent United States funds, using the exchange rate
quoted in the Wall Street Journal on the last business day of the reporting period. In no event shall the Licensee be required to pay The Regents more than twenty-five (25%) of its total annual revenue derived from Licensed Products.

 4.6 Earned royalties earned on sales occurring in any country outside the United States may not be reduced by any taxes, fees, or
other charges imposed by the government of such country on the payment of royalty income. The Licensee is also responsible for all bank transfer charges. Notwithstanding this, all payments made by the Licensee in fulfillment of The Regents’ tax
liability in any particular country will be credited against earned royalties or fees due The Regents for sales of Licensed Products in that country. 
  

 -5- 

 4.7 If at any time legal restrictions prevent the prompt remittance of earned royalties by the
Licensee from any country where a Licensed Product is sold, the Licensee shall deposit the amount owed in an interest-bearing account within that country until such time as the restrictions are lifted, at which time the Licensee shall promptly
convert the current balance of said account into United States funds and pay such amount to The Regents. 
 4.8 If any patent or Valid Claim
within Regents’ Patent Rights is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay earned royalties based on that patent or Valid
Claim or any Valid Claim patentably indistinct therefrom will cease as of the date of final decision. The Licensee will not, however, be relieved from paying any earned royalties that accrued before the final decision or that are based on
another patent within Regents’ Patent Right or Valid Claim not involved in the final decision. 
 4.9 If payments, rebillings or fees
are not received by The Regents when due, the Licensee shall pay to The Regents interest charges on the unpaid amount at a rate often percent (10%) per annum or the maximum permitted by law, whichever is less. Interest is calculated from the
date due until actually received by The Regents. 
 5. LICENSE-ISSUE FEE 
 5.1 Within sixty (60) days after the Effective Date, the Licensee shall pay to The Regents a license-issue fee equal to the total amount of out-of-pocket costs and expenses of patent prosecution of the
Regents’ Patent Rights incurred by The Regents through the Effective Date. This fee is non-refundable, non-cancelable, and is not an advance against earned royalties. 
 6. LICENSE MAINTENANCE FEE 
 6.1 [Intentionally left blank] 
 7. EARNED ROYALTIES, MINIMUM ANNUAL ROYALTIES AND MILESTONE PAYMENTS 
 7.1 The Licensee shall also pay to The Regents an earned royalty of one-half percent (0.5%) of the Net Sales of Licensed Products worldwide, up to a maximum of one million dollars ($1,000,000) per year. 
 7.2 If it becomes necessary for Licensee to license intellectual property rights from an unaffiliated third party, and Licensee is required to pay a
royalty to that unaffiliated third party in order to practice Licensed Methods and make, use or sell Licensed Products, and the combined earned royalty due The Regents and unaffiliated third parties exceeds eleven percent (11%), then the
earned royalties to be paid to The Regents by Licensee shall be reduced by an amount equal to one-half (1/2) the excess over eleven percent (11%) of the royalty rate(s) due to the unaffiliated third party(ies). However, in no event
shall the amount paid to The Regents be reduced below fifty percent (50%) of the original earned royalty otherwise due The Regents. 
  

 -6- 

 7.3 No cumulation of earned royalties shall be made in the event a Licensed Product is covered by
Valid Claims of more than one patent within Regents’ Patent Rights. 
 7.4 No earned royalty shall be payable under this
Article 7 with respect to transfers of Licensed Product to Affiliates, Sublicensees, customers or prospective customers for use in research and/or development, in clinical trials or other regulatory purposes, as samples, or in any other
transfer that is not a Commercial Sale. 
 7.5 In the event that a Licensed Product is sold in combination with other products, components or
services (other than another Licensed Product having therapeutic activity) for which no amounts would be payable to The Regents if such other products, components or services having therapeutic activity were sold or performed separately, amounts
invoiced for such combination sales for purposes of calculating Net Sales of the Licensed Product in such combination shall be the Net Sales of the Licensed Product calculated by multiplying the Net Sales of the combination product by the fraction
A/B where A is the average price on a unit basis of Licensed Product containing a certain amount (by weight) of active ingredient, and B is the average unit price of the combination product containing the same amount of that active ingredient. In
the event that such average sale price cannot be determined for both the Licensed Product and the other product(s) in combination, Net Sales for purposes of determining royalty payment shall be mutually agreed by the parties based on relative value
contributed by each component, and such agreement shall not be unreasonably withheld. 
 7.6 [Intentionally left blank] 
 7.7 Licensee shall pay The Regents non-creditable milestone payments should either of the following occur while Commercial Sales or commercialization of
a Licensed Product by Licensee are continuing: (i) the closing of an Initial Public Offering (“IPO”) of the Licensee’s common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange
Commission; or (ii) the closing of (x) a consolidation or merger of the Licensee with any other entity, (y) sale of all or substantially all of the assets of Licensee, or (z) sale of all or substantially all of the outstanding
stock of the Licensee, pursuant to which the shareholders of the Licensee receive cash or publicly traded securities. Upon the occurrence of such event, the Licensee shall pay to The Regents total cash payments equal to X times P, where X is equal
to 16,400 stock equivalents (which number of stock equivalents shall be subject to adjustment from time to time for any stock split, stock dividends, recapitalizations a the like) and P is equal to either the IPO offering price per share of common
stock, or in the case of a merger, acquisition, or sale, the average price per share actually received by shareholders of the Licensee’s common stock from the acquirer. Such payments shall be paid in three (3) installments, with one third
(1/3) of the total to be paid twelve (12) months after the closing date of such transaction, one third (1/3) to be paid twenty four (24) months after such closing date, and the remaining one third (1/3) to be paid thirty six
(36) months after such closing date. In the event that the transaction contemplated hereunder involves more than one closing date, the due date for payments owed to The Regents shall be measured from the date of the last closing. 
  

 -7- 

 7.8 Notwithstanding the foregoing Section 7.7, no milestone payments shall be due from Licensee
under Section 7.7 in the event that: (i) a patent with a claim covering a Licensed Product has not issued under the Regents’ Patent Rights at the time such milestone payment is due; and (ii) The Regents is no longer funding
active prosecution of the Regents’ Patent rights in the United States patent office or a foreign equivalent; and (iii) the first Commercial Sale of a Licensed Product has already occurred. 
 8. DUE DILIGENCE 
 8.1 The Licensee, on execution of this
Agreement, shall use commercially reasonable efforts to develop, manufacture and sell Licensed Products, or cause a Sublicensee to do so, and shall use the same level of effort to market the same within a reasonable time after execution of this
Agreement. 
 8.2 The Licensee shall use commercially reasonable efforts to obtain all governmental approvals necessary for the manufacture,
use and sale of Licensed Products. 
 8.3 The Licensee shall commit to use commercially reasonable efforts (either itself or through a
Sublicensee) to develop and commercialize at least one Licensed Product, including achievement of the following milestones: (i) dosing of the first human patient with a Licensed Product in support of a Phase I clinical trials by the end of
the third year after the Effective Date; (ii) filing at least one NDA by November 1, 2009; and (iii) commencing the marketing of at least one Licensed Product in one country by November 1, 2011. 
 8.4 If the Licensee fails to complete any of the above provisions, and The Regents does not otherwise extend or waive such period of performance, then
The Regents has the right and option to terminate this Agreement pursuant to Paragraph 12.1 or, upon consent of Licensee, reduce the Licensee’s exclusive license to a nonexclusive license. This right, if exercised by The Regents, supersedes the
rights granted in Article 2 (GRANT). 
 9. PROGRESS AND ROYALTY REPORTS 
 9.1 Beginning February 28, 2002 and semi-annually thereafter, the Licensee shall submit to The Regents a progress report covering the Licensee’s (and any Affiliate or Sublicensee’s) activities regarding
the development and testing of all Licensed Products and the obtaining of any governmental approvals necessary for marketing. Progress reports are required until the first Commercial Sale of the first Licensed Product occurs in the United States, at
which time the Licensee may discontinue such reports; provided that such reports may again be required by The Regents if Commercial Sales of such Licensed Product are suspended or discontinued. 
 9.2 Progress reports submitted under Paragraph 9.1 shall include, but are not limited to, the following topics, as they specifically refer to Licensed
Products: 
  

	 	•	 	 summary of work completed 

  

	 	•	 	 key scientific discoveries 

  

	 	•	 	 summary of work in progress 

  

	 	•	 	 current schedule of anticipated events or milestones 

  

 -8- 

	 	•	 	 market plans for introduction of Licensed Products, and 

  

	 	•	 	 a summary of resources (dollar value) spent in the reporting period. 

 9.3 The Licensee has a continuing obligation to keep The Regents’ informed of the large/small business entity status (as defined by the United
States Patent and Trademark Office) of itself and its Sublicensees and Affiliates. 
 9.4 The Licensee shall report to The Regents the date
of first Commercial Sale of a Licensed Product in each country in its immediately subsequent royalty report (as described below). 
 9.5
After the first Commercial Sale of a Licensed Product anywhere in the world, the Licensee shall make quarterly royalty reports to The Regents on or before each February 28, May 31, August 31 and November 30 of each year. Each
royalty report will cover the Licensee’s most recently completed calendar quarter and will show (a) the gross sales and Net Sales of Licensed Products sold during the most recently completed calendar quarter; (b) the number of each
type of Licensed Product sold; (c) the earned royalties, in U.S. dollars, payable with respect to sales of Licensed Products; (d) the method used to calculate the earned royalties; and (e) the exchange rates used (if
applicable). 
 9.6 If no sales of Licensed Products have been made during any reporting period, Licensee shall provide a statement to this
effect. 
 10. BOOKS AND RECORDS 
 10.1 The
Licensee shall keep accurate books and records showing all Licensed Products manufactured, used, and/or sold under the terms of this Agreement. Books and records must be preserved for at least five (5) years from the date of the royalty payment
to which they pertain. 
 10.2 The Regents is entitled to have a mutually acceptable independent auditor under a duty of confidentiality
inspect these books and records during regular office hours for the purpose of verifying the payment of earned royalties and sublicense payments due hereunder with respect to Net Sales and sublicense fees received by Licensee not more
than five (5) years prior to the date of The Regents’ request. The Regents may exercise its right to review Licensee’s books and records not more than once per calendar year and must provide Licensee at least fourteen (14) days
advance written notice. The auditor shall only report to The Regents the amount of under or over payment of earned royalties and sublicense fees, if any. The Regents shall bear the fees and expenses of examination but if an error in
royalties of more than five percent (5%) of the total royalties due for any year is discovered in any examination then the Licensee shall bear the fees and expenses of that examination. The information learned by The Regents pursuant to this
Paragraph 10.2 or contained in reports provided to The Regents under Article 9 above shall be deemed Data of Licensee for purposes of Article 29 below. 
 11. LIFE OF THE AGREEMENT 
 11.1 Unless otherwise terminated by operation of law or by acts of the parties in accordance with the
terms of this Agreement, this Agreement will be in force from the Effective Date and shall expire on a country-by-country basis as to each Licensed Product on the date that 
  

 -9- 

 
neither the sale nor use of such Licensed Product would be covered by a Valid Claim in such country. This Agreement shall expire in its entirety, unless
otherwise terminated or otherwise provided herein, upon the last expiration date of a patent licensed under this Agreement; or until the last patent application licensed under this Agreement is abandoned and no patent in Regents’ Patent Rights
ever issues. 
 11.2 Any termination of this Agreement will not affect the rights and obligations set forth in the following Articles:

  

			
	Article 1	  	Definitions
	Paragraph 3.4	  	Survival of Sublicenses
	Article 10	  	Books and Records
	Article 14	  	Disposition of Licensed Products on Hand on Termination
	Article 15	  	Use of Names and Trademarks
	Article 20	  	Indemnification
	Article 24	  	Failure to Perform
	Article 29	  	Secrecy
	Article 30	  	Miscellaneous

 12. TERMINATION BY THE REGENTS 
 12.1 If the Licensee fails to materially perform or materially violates any term of this Agreement, then The Regents may give written notice of default (“Notice of Default”) to the Licensee. If the Licensee
fails to repair the default within sixty (60) days of the effective date of Notice of Default, The Regents may terminate this Agreement and its licenses by a second written notice (Notice of Termination). However, if Licensee disputes the
alleged breach within the cure period, then The Regents shall not have the right to terminate this Agreement unless it has been determined by an arbitrator or court proceeding that this Agreement was materially breached, and Licensee fails to comply
with its obligations hereunder within sixty (60) days after that determination. If a properly given Notice of Termination is sent to the Licensee, this Agreement will automatically terminate on the effective date of such Notice. Termination
will not relieve the Licensee of its obligation to pay any fees owing at the time of termination and will not impair any accrued right of The Regents. These notices are subject to Article 21 (Notices). 
 13. TERMINATION BY LICENSEE 
 13.1 The Licensee has the right
at any time to terminate this Agreement in whole or as to any portion of Regents’ Patent Rights by giving notice in writing to The Regents. Notice of termination will be subject to Article 21 (Notices) and termination of this Agreement will be
effective sixty (60) days from the effective date of notice. 
 13.2 Any termination under the above paragraph does not relieve the
Licensee of any obligation or liability accrued under this Agreement prior to termination or rescind any payment made to The Regents or anything done by Licensee prior to the time termination becomes effective. Termination does not affect in any
manner any rights of The Regents arising under this Agreement prior to termination. 
  

 -10- 

 14. DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION 
 14.1 Upon termination of this Agreement the Licensee is entitled to dispose of all previously made or partially made Licensed Products, but no more,
within a period of one hundred and eighty (180) days provided that the sale of those Licensed Products is subject to the terms of this Agreement, including but not limited to the rendering of reports and payment of royalties required under this
Agreement 
 15. USE OF NAMES AND TRADEMARKS 
 15.1 Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation
or simulation of any of the foregoing). Unless required by law, the use by the Licensee of the name “The Regents of the University of California” or the name of any campus of the University of California is prohibited. 
 16. LIMITED WARRANTY 
 16.1 The Regents, as represented by
the actual knowledge of the undersigned on behalf of the Regents as of the Effective Date, warrants to the Licensee that that it owns all right, title, and interest in and to the Regents’ Patent Rights, and that it has the lawful right to grant
this license. 
 16.2 This license and the associated Invention are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. THE REGENTS MAKES NO REPRESENTATION OR WARRANTY THAT THE LICENSED PRODUCTS OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT OF A THIRD PARTY. 
 16.3 IN NO EVENT WELL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR
THE USE OF THE INVENTION OR LICENSED PRODUCTS. 
 16.4 This Agreement does not: 
 16.4.1 express or imply a warranty or representation as to the validity or scope of any of Regents’ Patent Rights; 
 16.4.2 express or imply a warranty or representation that anything made, used, sold, offered for sale or imported or otherwise disposed of under any
license granted in this Agreement is or will be free from infringement of patents of third parties; 
 16.4.3 obligate The Regents to bring
or prosecute actions or suits against third parties for patent infringement except as provided in Article 19; 
 16.4.4 confer by
implication, estoppel or otherwise any license or rights under any patents of The Regents other than Regents’ Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Regent’s Patent
Rights; or 
  

 -11- 

 16.4.5 obligate The Regents to furnish any know-how not provided in Regents’ Patent Rights.

 17. PATENT PROSECUTION AND MAINTENANCE 
 17.1
As long as the Licensee has paid patent costs as provided for in this Article, The Regents shall diligently prosecute and maintain the United States and foreign patents comprising Regents’ Patent Rights using counsel of its choice, reasonably
acceptable to Licensee. If Licensee objects to the choice of patent counsel, then The Regents shall appoint an alternative choice of patent counsel with Licensee’s approval. The Regents shall provide the Licensee with copies of all relevant
documentation and correspondence so that the Licensee may be informed of the continuing prosecution and submit timely comments and guidance for consideration by patent counsel. The Licensee agrees to keep such correspondence and documentation
confidential. The Regents agrees to allow Licensee to submit advice, counsel, and guidance regarding patent prosecution to The Regents’ counsel, although such counsel will take instructions only from The Regents. All patents and patent
applications under this Agreement which are based solely on research performed at UCSF and filed prior to the Execution Date will be assigned solely to The Regents, subject to the grant of exclusive rights hereunder. 
 17.2 The Regents shall use best efforts to amend any patent application to include claims reasonably requested by the Licensee to protect the products
contemplated to be sold under this Agreement and shall ensure that the Licensee is kept apprised of patent-related activities so that it may provide such requests in a timely manner. 
 17.3 The Licensee shall, if appropriate in Licensee’s business judgment, apply for an extension of the term of any patent included within
Regents’ Patent Rights under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this Law. If Licensee elects to apply for such extension, Licensee shall prepare all
documents, and The Regents agrees to execute the documents and to take additional action as the Licensee reasonably requests in connection therewith. 
 17.4 If either party (in the case of the Regents, the actual knowledge of the Licensing Officer responsible for administration of this Agreement) receives notice from a third party pursuant to 21 CFR §314.95(a)
stating that one or more patents within the Regents’ Patent Rights is invalid, unenforceable or not infringed by the manufacture, use or sale of a drug product for which such third party has submitted an ANDA under 21 CFR
§§314.92–314.99 (or an equivalent notice with respect to a drug product for which such third party has submitted a marketing application under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act), then that party shall
notify the other party within ten (10) days after receipt of notice of infringement. 
 17.5 The Regents shall bear the costs of
preparing, filing, prosecuting and maintaining all United States and foreign patent applications contemplated by this Agreement incurred after the Effective Date, and as required under Article 5 and Section 17.6. 
 17.6 The Licensee may request The Regents to obtain patent protection on the Invention in foreign countries if available and if it so desires. The
Licensee shall notify The Regents of its 

  

 -12- 

 
decision to obtain or maintain foreign patents not less than sixty (60) days prior to the deadline for any payment, filing, or action to be taken in
connection therewith. This notice concerning foreign filing must be in writing and must identify the countries desired. The absence of such a notice from the Licensee to The Regents will be considered an election not to obtain or maintain foreign
rights. 
 17.7 Licensee may terminate its obligations with respect to any given patent application or patent upon three (3) months
written notice to The Regents. If such notice is received from the Licensee, The Regents may continue to prosecute and maintain such application(s) or patent(s) at its sole discretion and expense, but the Licensee will have no further right or
licenses thereunder. If Licensee does not provide such a notice of termination as to any given patent application or patent within The Regents’ patent Rights, then The Regents’ obligation to underwrite and to pay patent prosecution costs
will continue for so long as this Agreement remains in effect. 
 17.8 [Intentionally left blank] 
 18. PATENT MARKING 
 18.1 The Licensee shall mark all
Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. 
 19.
PATENT INFRINGEMENT 
 19.1 If The Regents (to the extent of the actual knowledge of the licensing professional responsible for the
administration of this Agreement) or the Licensee learns of the substantial infringement of any patent licensed under this Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with
any evidence of such infringement available to it (the “Infringement Notice”). Neither party will notify a third party of the infringement of any of Regents’ Patent Rights without first obtaining consent of the other party, which
consent will not be unreasonably denied or delayed. Both parties shall use their best efforts in cooperation with each other to terminate infringement without litigation. 
 19.2 If the infringing activity has not been abated within ninety (90) days following the date the Infringement Notice takes effect, then the Licensee or its designee may institute suit for patent infringement
against the infringer. The Regents may voluntarily join such suit at its own expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of the Licensee’s suit or any judgment rendered
in the suit. The Licensee may not join The Regents in a suit initiated by Licensee without The Regents’ prior written consent. If, in a suit initiated by the Licensee, The Regents is involuntarily joined other than by the Licensee, then the
Licensee will pay any out-of-pocket costs incurred by The Regents arising out of such suit, including but not limited to, legal fees of counsel that The Regents selects and retains to represent it in the suit. The Regents will join as a party to any
suit initiated by Licensee if found to be a necessary party by a court of law. 
 19.3 If, within a hundred and eighty (180) days
following a request by The Regents that Licensee take action to abate the infringing activity, the infringing activity of potential commercial significance by the infringer has not been abated and the Licensee or it designee has not brought suit

  

 -13- 

 
against the infringer or begun negotiations regarding the terms under which Licensee would grant a sublicense to the infringer, then The Regents may
institute such suit for patent infringement against the infringer. If The Regents institutes such suit, then the Licensee may not join such suit without The Regents’ consent and may not thereafter commence suit against the infringer for acts of
infringement that are subject to The Regents’ suit or any judgment rendered in that suit. The Regents may not join Licensee in a suit initiated by The Regents without Licensee’s prior written consent. 
 19.4 Legal action as is decided on will be at the expense of the party bringing suit, but legal action brought jointly by The Regents and the Licensee
and fully participated in by both will be at the joint expense of the parties. Any recovery or settlement received in connection with any suit will be applied as follows: (i) first to reimburse the controlling party for its out-of-pocket costs
and expenses (including attorneys’ and court costs and expenses and amounts reimbursed to the other party); (ii) next to reimburse the out-of-pocket costs and expenses of the other party; and (iii) any remainder after reimbursing the
amounts set forth in clause (i) and (ii) shall be retained by the controlling party; provided that if Licensee is the controlling party (or in the event that the action is jointly controlled), Licensee, while being entitled to retain any
remainder of such recovery, agrees to pay The Regents fifteen percent (15%) of such remainder, or to the extent of enhanced damages twenty five percent (25%) of such remainder. 
 19.5 Each party shall cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party bringing suit. Litigation
will be controlled by the party bringing the suit. 
 20. INDEMNIFICATION 
 20.1 The Licensee shall indemnify, hold harmless and defend The Regents, its officers, employees, and agents; the sponsors of the research that led to the invention; and the inventors of the patents and patent
applications in Regents’ Patent Rights and their employers against any and all claims, suits, losses, liabilities, damages, costs, fees, and expenses asserted by third parties (“Claims”) resulting from or arising out of exercise of
this license or any voluntary sublicense, except to the extent resulting from a breach of this Agreement by The Regents; provided that Licensee shall have no obligations with respect to any Claims unless the person or entity claiming under this
Paragraph 20.1 (i) promptly notifies Licensee in writing of such Claims, (ii) gives Licensee sole control of the defense and settlement thereof (provided that Licensee shall not admit to wrongdoing or liability on the part of The Regents
without the prior written consent of The Regents), and (iii) provides Licensee, at Licensee’s expense, with reasonable assistance and full information with respect to such Claims. This indemnification includes, but is not limited to, any
product liability. Notwithstanding the foregoing, the Licensee shall have no obligations for any claim if the person (as listed above) seeking indemnification makes any admission or settlement regarding such claim without the prior written consent
of the Licensee, which consent shall not be unreasonably withheld. 
 20.2 The Licensee, at its sole cost and expense, shall insure its
activities in connection with the work under this Agreement and obtain (not later than the start of Phase I clinical trials of a product intended for Commercial Sale), keep in force and maintain insurance as follows, or an equivalent program of
self insurance. 
  

 -14- 

 20.3 Comprehensive or commercial form general liability insurance (contractual liability included) with
limits as follows: 
  

	 	•	 	 Each Occurrence $1,000,000 

  

	 	•	 	 Products/Completed Operations Aggregate $5,000,000 

  

	 	•	 	 Personal and Advertising Injury $1,000,000 

  

	 	•	 	 General Aggregate (commercial form only) $5,000,000 

 The coverage and limits referred to under the above do not in any way limit the liability of the Licensee. The Licensee shall furnish The Regents with certificates of insurance showing compliance with all requirements. Certificates must:

  

	 	•	 	 Provide for thirty (30) days’ advance written notice to The Regents of any modification. 

  

	 	•	 	 Indicate that The Regents has been endorsed as an additional Insured under the coverage referred to under the above. 

  

	 	•	 	 Include a provision that the coverage will be primary and will not participate with nor will be excess over any valid and collectable insurance or program of
self-insurance carried or maintained by The Regents. 

 20.4 The Regents shall notify the Licensee in writing of any claim
or suit brought against The Regents in respect of which The Regents intends to invoke the provisions of this Article. The Licensee shall keep The Regents informed on a current basis of its defense of any claims under this Article. 
 21. NOTICES 
 21.1 Any notice or payment required to be given
to either party is properly given and effective (a) on the date of delivery if delivered in person or (b) five (5) days after mailing if mailed by first-class certified mail, postage paid, to the respective addresses given below, or
to another address as is designated by written notice given to the other party. 
  

					
		 	In the case of the Licensee:	  	 NeurogesX, Inc.
 2215 Bridgepointe Parkway, Suite 200
 San Mateo, CA 94404
 Attn: CEO

			
		 	In the case of The Regents:	  	 Office of Technology Management
 University of California San Francisco
 1294 Ninth Avenue - Box 1209
 San Francisco, CA 94143-1209
 Attention: Director
 Referring to: UCSF Case No. SF00-056

  

 -15- 

 22. ASSIGNABILITY 
 22.1 This Agreement may be assigned by The Regents, but is personal to the Licensee and assignable by the Licensee only with the written consent of The Regents, which consent will not be unreasonably withheld; provided that the Licensee may
assign this Agreement without The Regents’ consent to an entity that acquires substantially all of the business or assets of the Licensee (or that portion thereof to which this Agreement relates), in each case whether by merger, acquisition, or
otherwise the acquiring party assumes this Agreement in writing or by operation of law. 
 23. NO WAIVER 
 23.1 No waiver by either party of any default of this Agreement may be deemed a waiver of any subsequent or similar default. 
 24. FAILURE TO PERFORM 
 24.1 If either party finds it
necessary to undertake legal action against the other on account of failure of performance due under this Agreement, then the prevailing party is entitled to reasonable attorney’s fees in addition to costs and necessary disbursements.

 25. GOVERNING LAWS 
 25.1 THIS AGREEMENT WILL
BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and validity of any patent or patent application will be governed by the applicable laws of the country of the patent or patent application.

 26. PREFERENCE FOR UNITED STATES INDUSTRY 
 26.1 [Intentionally left blank] 
 27. GOVERNMENT APPROVAL OR REGISTRATION 
 27.1 Licensee shall notify The Regents if it becomes aware that this Agreement is subject to any U.S. or foreign government reporting or approval
requirement. Licensee shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process. 
 28. EXPORT CONTROL LAWS 
 28.1 The Licensee shall observe all applicable United States and foreign laws with
respect to the transfer of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. 
  

 -16- 

 29. SECRECY 
 29.1 If either party discloses confidential information (“Data”) to the other party, the disclosing party will designate this information as confidential by appropriate legend or instruction, e.g. “Confidential”
or “Proprietary”, and the receiving party will: 
 29.1.1 not to use the Data except for the sole purpose of accomplishing the
objectives of this Agreement; 
 29.1.2 to safeguard Data against disclosure to others with the same degree of care as it exercises with its
own data of a similar nature, but in no event less than reasonable care; 
 29.1.3 not to disclose Data to others (except to its employees,
agents, consultants, distributors, sublicensees, potential and actual investors and others who have a need to know and who are bound to the Licensee by a like obligation of confidentiality) without the express written permission of The Regents,

 29.1.4 Neither party will have any confidentiality obligation with respect to Data belonging to or disclosed by the other party that:

 (i) the receiving party can demonstrate by written records was previously known to it; 
 (ii) is now, or becomes in the future, public knowledge other than through acts or omissions of the receiving party; 
 (iii) is lawfully obtained by the receiving party from sources independent of the disclosing party; 
 (iv) is independently developed by the receiving party without use of the Data of the disclosing party; and 
 29.1.5 that the secrecy obligations of the parties with respect to Data will continue for a period ending five (5) years from the termination date
of this Agreement. 
 29.1.6 The non-disclosure obligations contained in Article 29 shall not apply to particular Data that a receiving
party received from the other party to the extent that such receiving party is required to disclose such Data by law, order or regulation of a governmental agency (including the California Public Records Act or governmental audit requirement) or a
court of competent jurisdiction, provided that such receiving party first gives reasonable notice of such requirement to the disclosing party, removes the then actual trade secrets of the disclosing party upon request and as directed by the
disclosing party to the extent permitted by law, and cooperates with the disclosing party in the event the disclosing party challenges the requirement and/or scope of such disclosure. 
  

 -17- 

 30. MISCELLANEOUS 
 30.1 The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 
 30.2 This Agreement is not binding on the parties until it has been signed below on behalf of each party. It is then effective as of the Effective Date.

 30.3 No amendment or modification of this Agreement is valid or binding on the parties unless made in writing and signed on behalf of each
party. 
 30.4 For the purposes of this Agreement and all services to be provided hereunder, the parties shall be, and shall be deemed to be,
independent contractors and not agents or employees of either of the other parties. No party shall have authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on either of the other
parties, except as may be expressly provided for herein or authorized in writing. 
 30.5 This Agreement embodies the entire understanding of
the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. The Secrecy Agreement effective August 20, 1999 (U.C. Control
No. 2000-20-0104) is hereby terminated. 
 30.6 In case any of the provisions contained in this Agreement is held to be invalid,
illegal, or unenforceable in any respect, that invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and this Agreement will be construed as if the invalid, illegal, or unenforceable provisions had never
been contained in it. 
 30.7 In the event that, within one (1) year after the Amendment Date, Licensee agrees, at its sole discretion,
to accept an assignment or license of rights to US Patent Application Serial No. 08/746,207 from Messrs. Staats and Pappagallo (or their executors, successors, or assigns), named inventors on such Application, such that Licensee has exclusive
rights under such Application, The Regents and Licensee agree that the paragraphs 1-8, 10-12 of [Amendment Number One] shall be rescinded as of the date such assignment or license is perfected, and the original terms of the Agreement shall apply
thereafter. In addition, Licensee shall be entitled to deduct its costs and expenses incurred with respect to such assignment or license, as well as any on-going royalty obligations, from any amounts due The Regents hereunder after the date such
assignment or license is perfected. 
 [Signature Page Follows] 
  

 -18- 

 IN WITNESS WHEREOF, both The Regents and the Licensee have executed this Agreement, in duplicate
originals, by their respective and duly authorized officers on the day and year written. 
  

									
	LICENSEE	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By:	  	 /s/    Tony DiTonno
	 		 	By:	 	 /s/    Joel B. Kirschbaum

		  	(Signature)	 		 		 	(Signature)
					
	Name:	  	 Tony DiTonno
	 		 	Name:	 	 Joel B. Kirschbaum

		  	(Please Print)	 		 		 	(Please Print)
					
	Title:	  	CEO	 		 	Title:	 	Director - OTM
					
	Date:	  	 10/6/08
	 		 	Date:	 	 10/6/08

  

 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]